Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857240 · ClinicalTrials.gov registry record · Phase 2
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
A Phase 2 study of Dermatomyositis, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06857240 is a Phase 2 study of Dermatomyositis that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 15 participants, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06857240, a Phase 2 study of Dermatomyositis, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
Conditions Studied
Interventions
- DRUG Ruxolitinib Topical Cream
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06857240
The ClinicalTrials.gov registry entry for NCT06857240 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (97% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Topical Cream is the first listed.
NCT06857240 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06857240 about?
NCT06857240 is a clinical study titled "Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis". This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
What is the current status of trial NCT06857240?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-06-01. Estimated completion is 2027-12.
What conditions does trial NCT06857240 study?
This clinical trial studies the following conditions: Dermatomyositis.
What interventions are being tested in trial NCT06857240?
The interventions under investigation include: Ruxolitinib Topical Cream (DRUG).
Who is sponsoring clinical trial NCT06857240?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857240 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
-
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.